好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prediction of Long-term Adherence to Smartphone Sensor-based Tests (Floodlight)
Multiple Sclerosis
P5 - Poster Session 5 (5:30 PM-6:30 PM)
6-016
Understanding and predicting long-term adherence to Floodlight smartphone sensor-based tests in people with progressive multiple sclerosis (PwPMS), treated with ocrelizumab in CONSONANCE (NCT03523858).

Adherence remains a challenge for deploying remote digital health solutions, as their utility often depends upon obtaining sufficient data over a period of time. Understanding adherence patterns could enable patient-tailored interventions that boost long-term adherence.

Participants performed sensor-based tests, using a precursor to Floodlight™ MS, assessing their cognition (weekly), upper extremity function (daily), gait and balance (daily); and passive monitoring of gait (≥4 hours daily) for up to 3 years. Unsupervised Hierarchical Agglomerative Clustering was used to identify five adherence clusters. The drop-out date (the first day of the first period of 4 weeks of inactivity) was predicted via a linear model that used the first 2 months of adherence data as predictors.

Of 633 enrolled participants, 348 were included in the analysis. The five adherence clusters identified were: High Adherence (n=81; 23.3%), Slow Decrease (n=119; 34.2%), Fast Decrease (n=67; 19.3%), Low Adherence (n=50; 14.4%) and No Gait (n=31; 8.9%). No significant differences were observed in age (Mann–Whitney U test: all p>0.05) or sex (absolute Pearson residuals: all <0.40) of PwPMS between the clusters. Good correlation was found between the predicted and actual drop-out dates (Pearson r=0.80). Higher adherence was associated with later drop out, and most High Adherence participants (74/81; 91.4%) showed no inactivity period.

Adherence during the first 2 months of using Floodlight technology can predict the time of inactivity of participants. Understanding adherence patterns may enable early, adherence-boosting interventions that focus on participants at risk of dropping out of remotely administered digital health studies, leading to an increase in data collection and improved engagement of PwPMS.

Authors/Disclosures
Marisa P. McGinley, DO (Cleveland Clinic)
PRESENTER
Dr. McGinley has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. McGinley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. The institution of Dr. McGinley has received research support from Biogen. The institution of Dr. McGinley has received research support from Genentech. The institution of Dr. McGinley has received research support from NIH. The institution of Dr. McGinley has received research support from AHRQ. The institution of Dr. McGinley has received research support from EMD Serono.
Gregoire Pointeau No disclosure on file
Mattia Zanon (F. Hoffmann-La Roche Ltd) No disclosure on file
Letizia M. Leocani, MD (University Vita-Salute San Raffaele, INSPE) Dr. Leocani has received personal compensation in the range of $0-$499 for serving as a Consultant for Roche . Dr. Leocani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Leocani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Leocani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Med-ex learning.
Giancarlo Comi, MD (University Vita-Salute) Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aspen Healthcare. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Rewind.
Florian Lipsmeier No disclosure on file
Licinio M. Craveiro, MD, PhD (Roche) Dr. Craveiro has received personal compensation for serving as an employee of Hoffmann La-Roche. Dr. Craveiro has received stock or an ownership interest from Hoffmann La-Roche.
Helmut Butzkueven, MD, MBBS Dr. Butzkueven has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Oxford Health Policy Forum. The institution of Dr. Butzkueven has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. The institution of Dr. Butzkueven has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck. The institution of Dr. Butzkueven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. The institution of Dr. Butzkueven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Butzkueven has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for MSBase . The institution of Dr. Butzkueven has received research support from NHMRC. The institution of Dr. Butzkueven has received research support from Biogen. The institution of Dr. Butzkueven has received research support from Roche. The institution of Dr. Butzkueven has received research support from Novartis.